← Back to headlines
Analysts Project Strong Growth for Teva, Edison, and Neurocrine Biosciences
Goldman Sachs anticipates double-digit earnings growth for Teva Pharmaceutical Industries through 2026, while Edison International posts strong 2025 results and sets 2026–2027 EPS targets. Needham is bullish on Neurocrine Biosciences' pipeline, expecting growth from Crenessity and Ingrezza by 2026.
19 Feb, 02:33 — 19 Feb, 02:33
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Fed’s Hammack: Monetary Policy Is in a Good Place to Stay on Hold - The Wall Street Journal
11m ago
Investment Recommendation: 2 Stocks Under $30 to Buy in 2026
11m ago
Cameco Stock Drops Below $120, Prompts Buy Consideration
11m ago
Crypto Startups Raise $95 Million Led by Prediction Markets and AI Agents
11m ago